Baicalin serves a protective role in diabetic nephropathy through preventing high glucose‑induced podocyte apoptosis

Li,Jindong; Ling,Ya; Yin,Shengnan; Yang,Shufang; Kong,Min; Li,Zhiqin

doi:10.3892/etm.2020.8701

Baicalin serves a protective role in diabetic nephropathy through preventing high glucose‑induced podocyte apoptosis

Authors:
- Jindong Li
- Ya Ling
- Shengnan Yin
- Shufang Yang
- Min Kong
- Zhiqin Li
View Affiliations

Affiliations: Department of Pharmacy, Hospital Affiliated 5 to Nantong University, Taizhou People's Hospital, Taizhou, Jiangsu 225300, P.R. China, Department of Pharmacy, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215006, P.R. China, Department of Pharmacy, Hospital of Traditional Chinese Medicine of Taizhou, Taizhou, Jiangsu 225300, P.R. China
Published online on: April 29, 2020 https://doi.org/10.3892/etm.2020.8701
Pages: 367-374
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Diabetic nephropathy (DN) is one of the late complications of diabetes, which seriously affects the lives of patients. Baicalin (BA) is a flavone glycoside that has been identified to improve renal function in patients with DN. The present study aimed to investigate the roles and mechanisms of BA in DN. For that purpose, podocytes were cultured for 48 h under conditions of high glucose (HG; 30 mM D‑glucose) or normal glucose (NG; 5 mM D‑glucose). Then, the cells were treated with different concentrations of BA (6.25, 12.5 and 25 µM) for 24 h. Cell viability and apoptosis were determined using an MTT assay and flow cytometry, respectively. Protein and mRNA expression levels were analyzed using western blotting and reverse transcription‑quantitative PCR, respectively. BA treatment was identified to promote the viability of podocytes and suppress cell apoptosis in a dose‑dependent manner. Compared with the results in the NG group, HG stimulation significantly decreased the viability of podocytes and increased the apoptotic rate, whereas BA treatment following HG stimulation increased the viability of podocytes and decreased the apoptotic rate. Moreover, the effect of BA was revealed to be associated with the sirtuin 1/NF‑κB signaling pathway in DN. In conclusion, the results of the present study suggested that BA treatment may significantly decrease HG‑induced podocyte apoptosis, which indicated that BA might be a promising agent for DN treatment.

View Figures

View References

1	Yang M, Kan L, Wu L, Zhu Y and Wang Q: Effect of baicalin on renal function in patients with diabetic nephropathy and its therapeutic mechanism. Exp Ther Med. 17:2071–2076. 2019.PubMed/NCBI View Article : Google Scholar
2	Akhtar M, Taha NM, Nauman A, Mujeeb IB and Al-Nabet ADMH: Diabetic kidney disease: Past and present. Adv Anat Pathol. 27:87–97. 2020.PubMed/NCBI View Article : Google Scholar
3	Fu J, Lee K, Chuang PY, Liu Z and He JC: Glomerular endothelial cell injury and cross talk in diabetic kidney disease. Am J Physiol Renal Physiol. 308:F287–F297. 2017.PubMed/NCBI View Article : Google Scholar
4	Nath KA: Tubulointerstitial changes as a major determinant in the progression of renal damage. Am J Kidney Dis. 20:1–17. 1992.PubMed/NCBI View Article : Google Scholar
5	Kowalski A, Krikorian A and Lerma EV: Diabetic nephropathy for the primary care provider: New understandings on early detection and treatment. Ochsner J. 14:369–379. 2014.PubMed/NCBI
6	Papadopoulou-Marketou N, Kanaka-Gantenbein C, Marketos N, Chrousos GP and Papassotiriou I: Biomarkers of diabetic nephropathy: A 2017 update. Crit Rev Clin Lab Sci. 54:326–342. 2017.PubMed/NCBI View Article : Google Scholar
7	Ying Q and Wu G: Molecular mechanisms involved in podocyte EMT and concomitant diabetic kidney diseases: An update. Ren Fail. 39:474–483. 2017.PubMed/NCBI View Article : Google Scholar
8	Chen J, Chen JK and Harris RC: EGF receptor deletion in podocytes attenuates diabetic nephropathy. J Am Soc Nephrol. 26:1115–1125. 2015.PubMed/NCBI View Article : Google Scholar
9	Luo J, Dong B, Wang K, Cai S, Liu T, Cheng X, Lei D and Chen Y, Li Y, Kong J and Chen Y: Baicalin inhibits biofilm formation, attenuates the quorum sensing-controlled virulence and enhances Pseudomonas aeruginosa clearance in a mouse peritoneal implant infection model. PLoS One. 12(e0176883)2017.PubMed/NCBI View Article : Google Scholar
10	Jia Y, Chen L, Guo S and Li Y: Baicalin induced colon cancer cells apoptosis through miR-217/DKK1-mediated inhibition of wnt signaling pathway. Mol Biol Rep. 46:1693–1700. 2019.PubMed/NCBI View Article : Google Scholar
11	Wang XF, Zhou QM, Du J, Zhang H, Lu YY and Su SB: Baicalin suppresses migration, invasion and metastasis of breast cancer via p38MAPK signaling pathway. Anticancer Agents Med Chem. 13:923–931. 2013.PubMed/NCBI View Article : Google Scholar
12	Cao HJ, Yan YB, Dai JY, et al: Effect of baicalin on human lung cancer A549 cell line. Chin J Exp Tradit Med Formul. 19:216–220. 2013.(In Chinese).
13	Yi QQ, Xia YY, Chen J, et al: Baicalin improves diabetic nephropathy in mice by activating Sirt1/Nrf2 signal through miR-141 inhibition. Med J Wuhan Uni. 40:186–191. 2019.(In Chinese).
14	Sun QR, Zhang X and Fang K: Phenotype of vascular smooth muscle cells (VSMCs) is regulated by miR-29b by targeting sirtuin 1. Med Sci Monit. 24:6599–6607. 2018.PubMed/NCBI View Article : Google Scholar
15	Morigi M, Perico L and Benigni A: Sirtuins in renal health and disease. J Am Soc Nephrol. 29:1799–1809. 2018.PubMed/NCBI View Article : Google Scholar
16	Kitada M, Kume S, Takeda-Watanabe A, Kanasaki K and Koya D: Sirtuins and renal diseases: Relationship with aging and diabetic nephropathy. Clin Sci (Lond). 124:153–164. 2013.PubMed/NCBI View Article : Google Scholar
17	Shen HM and Tergaonkar V: NF-κB signaling in carcinogenesis and as a potential molecular target for cancer therapy. Apoptosis. 14:348–363. 2009.PubMed/NCBI View Article : Google Scholar
18	Deng X, Sun L, Lai X, Xiang L, Li Q, Zhang W, Zhang L and Sun S: Tea polypeptide ameliorates diabetic nephropathy through RAGE and NF-κB signaling pathway in type 2 diabetes mice. J Agric Food Chem. 66:11957–11967. 2018.PubMed/NCBI View Article : Google Scholar
19	Liu T, Zhang L, Joo D and Sun SC: NF-κB signaling in inflammation. Signal Transduct Target Ther. 2(17023)2017.PubMed/NCBI View Article : Google Scholar
20	Kuhad A and Chopra K: Attenuation of diabetic nephropathy by tocotrienol: Involvement of NF-kB signaling pathway. Life Sci. 84:296–301. 2009.PubMed/NCBI View Article : Google Scholar
21	Zhu L, Han J, Yuan R, Xue L and Pang W: Berberine ameliorates diabetic nephropathy by inhibiting TLR4/NF-κB pathway. Biol Res. 51(9)2018.PubMed/NCBI View Article : Google Scholar
22	Xu L, Zhang P, Guan H, Huang Z, He X, Wan X, Xiao H and Li Y: Vitamin D and its receptor regulate lipopolysaccharide-induced transforming growth factor-β, angiotensinogen expression and podocytes apoptosis through the nuclear factor-κB pathway. J Diabetes Investig. 7:680–688. 2016.PubMed/NCBI View Article : Google Scholar
23	Zhang SZ, Qiu XJ, Dong SS, Zhou LN, Zhu Y, Wang MD and Jin LW: MicroRNA-770-5p is involved in the development of diabetic nephropathy through regulating podocyte apoptosis by targeting TP53 regulated inhibitor of apoptosis 1. Eur Rev Med Pharmacol Sci. 23:1248–1256. 2019.PubMed/NCBI View Article : Google Scholar
24	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
25	Kawada T: Risk factors for developing prediabetes. Diabetes Res Clin Pract. 135(232)2018.PubMed/NCBI View Article : Google Scholar
26	Peng XD, Dai LL, Huang CQ, He CM and Chen LJ: Correlation between anti-fibrotic effect of baicalin and serum cytokines in rat hepatic fibrosis. World J Gastroenterol. 15:4720–4725. 2009.PubMed/NCBI View Article : Google Scholar
27	Roy MK, Nakahara K, Na TV, Trakoontivakorn G, Takenaka M, Isobe S and Tsushida T: Baicalein, a flavonoid extracted from a methanolic extract of oroxylum indicum inhibits proliferation of a cancer cell line in vitro via induction of apoptosis. Pharmazie. 62:149–153. 2007.PubMed/NCBI
28	Li HY, Hu J, Zhao S, Yuan ZY, Wan HJ, Lei F, Ding Y, Xing DM and Du LJ: Comparative study of the effect of baicalin and its natural analogs on neurons with oxygen and glucose deprivation involving innate immune reaction of TLR2/TNF-α. J Biomed Biotechnol. 2012(267890)2012.PubMed/NCBI View Article : Google Scholar
29	Moghaddam E, Teoh BT, Sam SS, Lani R, Hassandarvish P, Chik Z, Yueh A, Abubakar S and Zandi K: Baicalin, a metabolite of baicalein with antiviral activity against dengue virus. Sci Rep. 4(5452)2014.PubMed/NCBI View Article : Google Scholar
30	Nayak MK, Agrawal AS, Bose S, Naskar S, Bhowmick R, Chakrabarti S, Sarkar S and Chawla-Sarkar M: Antiviral activity of baicalin against influenza virus H1N1-pdm09 is due to modulation of NS1-mediated cellular innate immune responses. J Antimicrob Chemoth. 69:1298–1310. 2014.PubMed/NCBI View Article : Google Scholar
31	Chen J, Li Z, Chen AY, Ye X, Luo H, Rankin GO and Chen YC: Inhibitory effect of baicalin and baicalein on ovarian cancer cells. Int J Mol Sci. 14:6012–6025. 2013.PubMed/NCBI View Article : Google Scholar
32	Novy P, Urban J, Leuner O, Vadlejch J and Kokoska L: In vitro synergistic effects of baicalin with oxytetracycline and tetracycline against Staphylococcus aureus. J Antimicrob Chemoth. 66:1298–1300. 2011.PubMed/NCBI View Article : Google Scholar
33	Lee W, Ku SK and Bae JS: Anti-Inflammatory effects of baicalin, baicalein, and wogonin in vitro and in vivo. Inflammation. 38:110–125. 2015.PubMed/NCBI View Article : Google Scholar
34	Lu L, Rao L, Jia H, Chen J, Lu X, Yang G, Li Q, Lee KKH and Yang L: Baicalin positively regulates osteoclast function by activating MAPK/Mitf signaling. J Cell Mol Med. 21:1361–1372. 2017.PubMed/NCBI View Article : Google Scholar
35	Zheng J, Asakawa T, Chen Y, Zheng Z, Chen B, Lin M, Liu T and Hu J: Synergistic effect of baicalin and adriamycin in resistant HL-60/ADM leukaemia cells. Cell Physiol Biochem. 43:419–430. 2017.PubMed/NCBI View Article : Google Scholar
36	Ju XN, Mu WN, Liu YT, Wang MH, Kong F, Sun C and Zhou QB: Baicalin protects against thrombin induced cell injury in SH-SY5Y cells. Int J Clin Exp Pathol. 8:14021–14027. 2015.PubMed/NCBI
37	Morigi M, Perico L and Benigni A: Sirtuins in renal health and disease. J Am Soc Nephrol. 29:1799–1809. 2018.PubMed/NCBI View Article : Google Scholar
38	Chang HC and Guarente L: SIRT1 and other sirtuins in metabolism. Trends Endocrinol Metab. 25:138–145. 2014.PubMed/NCBI View Article : Google Scholar
39	Dai H, Sinclair DA, Ellis JL and Steegborn C: Sirtuin activators and inhibitors: Promises, achievements, and challenges. Pharmacol Ther. 188:140–154. 2018.PubMed/NCBI View Article : Google Scholar
40	Bible E: Diabetic nephropathy: Sirt1 attenuates diabetic albuminuria. Nat Rev Nephrol. 9(696)2013.PubMed/NCBI View Article : Google Scholar
41	Sakao Y, Kato A, Tsuji T, Yasuda H, Togawa A, Fujigaki Y, Kahyo T, Setou M and Hishida A: Cisplatin induces Sirt1 in association with histone deacetylation and increased Werner syndrome protein in the kidney. Clin Exp Nephrol. 15:363–372. 2011.PubMed/NCBI View Article : Google Scholar